Advertisement

Topics

Advanced Targeting Systems Company Profile

16:52 EDT 19th September 2017 | BioPortfolio

Targeted ToxinsAntibodies conjugated with our ribosome
inactivating protein, Saporin

Targeting Agents
Polyclonal Antibodies and Antibodies for Neuroscience

Custom Services
Conjugate synthesis between your targeting molecule and saporinan international.

Location

1600 Faraday Avenue
Carlsbad
CA
92008
United States of America

Contact

Phone: 619 889 2287
Fax: 619 755 7427
Email: ats@atsbio.com


News Articles [1906 Associated News Articles listed on BioPortfolio]

Pfizer Enters Feasibility Study Agreement Evaluating Alcyone’s Pulsar Technology for Use in Gene Therapy Targeting CNS Disorders

LOWELL, Mass., June 29, 2017 /PRNewswire/ — Alcyone Lifesciences, Inc., a leader in precision advanced central nervous system (CNS) delivery systems announced that it has entered into a feasibil...

Abbott, Bigfoot partner to develop advanced diabetes management systems

Healthcare firm Abbott has collaborated with Bigfoot Biomedical to develop and commercialize advanced diabetes management systems.

Excavation work proceeding according to plan at Advanced Oncotherapy's Harley Street site

Excavation work at Advanced Oncotherapy PLC’s (LON:AVO) flagship Harley Street site is progressing well and on time. The proton therapy systems developer said work has been completed on multiple s...

Ransom-Seeking Hackers Targeting Hospital Data

THURSDAY, May 11, 2017 -- Hackers are increasingly targeting hospitals, using viruses to lock their computer systems and hold sensitive medical data and other files hostage, according to a doctor in G...

Advanced Recovery Systems Supports Google's Advertising Restrictions for the Drug and Alcohol Rehab Industry

ORLANDO, Fla., Sept. 15, 2017 /PRNewswire/ -- Advanced Recovery Systems announces their full approval and support of Google's recent restrictions on paid advertising through their Adwords platfor...

CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies

CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to ...

Philips, Singapore Institute of Advanced Medicine Holdings to open new oncology center

Royal Philips and the Singapore Institute of Advanced Medicine Holdings (SAM) announced a collaboration with Varian Medical Systems and IBA Worldwide to build the new Advanced Medicine Oncology Centre...

Advanced algorithms, technology aim to improve on artificial pancreas systems

AUSTIN, Texas — Hybrid closed-loop control systems are poised to revolutionize diabetes management, and new, advanced algorithms and technology aim to further improve on the latest artificial pancre...

PubMed Articles [3807 Associated PubMed Articles listed on BioPortfolio]

Type III CRISPR-Cas systems: when DNA cleavage just isn't enough.

Type III CRISPR-Cas systems have a unique targeting mechanism that requires the transcription of the DNA target and results in the degradation of not only the genome of the invader but also its transc...

Guidelines for Developing Successful Short Advanced Courses in Systems Medicine and Systems Biology.

Systems medicine and systems biology have inherent educational challenges. These have largely been addressed either by providing new masters programs or by redesigning undergraduate programs. In contr...

Using CRISPR-Cas systems as antimicrobials.

Although CRISPR-Cas systems naturally evolved to provide adaptive immunity in bacteria and archaea, Cas nucleases can be co-opted to target chromosomal sequences rather than invasive genetic elements....

Programmable type III-A CRISPR-Cas DNA targeting modules.

The CRISPR-Cas systems provide invader defense in a wide variety of prokaryotes, as well as technologies for many powerful applications. The Type III-A or Csm CRISPR-Cas system is one of the most wide...

High tolerance to self-targeting of the genome by the endogenous CRISPR-Cas system in an archaeon.

CRISPR-Cas systems allow bacteria and archaea to acquire sequence-specific immunity against selfish genetic elements such as viruses and plasmids, by specific degradation of invader DNA or RNA. Howeve...

Clinical Trials [5233 Associated Clinical Trials listed on BioPortfolio]

Phase I Study of TENPA in Advanced Solid Cancer

The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in pa...

Effectiveness of Targeting Food Aid to Malnourished Children Compared to Targeting All Children Under Two Years

The objective of this study is to compare two approaches to targeting donated supplementary food to young children. The study compares the effectiveness of the widely-used curative approac...

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.

Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

Nimotuzumab is a humanized monoclonal anti-body targeting the epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications...

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Phase Ib study of the tumor-targeting human L19TNFα monoclonal antibody-cytokine fusion protein in combination with doxorubicin in patients with advanced solid tumors. This study foresee...

Companies [2496 Associated Companies listed on BioPortfolio]

Advanced Targeting Systems, Inc.

Immune Targeting Systems

Immune Targeting Systems is a London based biotech company developing vaccines for mutating viruses based on its broadly applicable next generation DepoVaccine and High Density (H...

Advanced Targeting Systems

Targeted ToxinsAntibodies conjugated with our ribosomeinactivating protein, Saporin Targeting AgentsPolyclonal Antibodies and Antibodies for Neuroscience Custom ServicesConjugate synthesis between you...

Advanced Pain Remedies

Headquartered near Research Triangle Park, NC, APR is majority owned and virtually run by Cato BioVentures. APR will work with Advanced Targeting Systems, Cato Research and Cato BioVentures to develop...

Advanced Neuromodulation Systems

Welcome to Advanced Neuromodulation Systems Successful treatment of a chronic pain or neurological condition begins with expanding your knowledge and exploring your options.Welcome to Advanced Neuromo...

More Information about "Advanced Targeting Systems" on BioPortfolio

We have published hundreds of Advanced Targeting Systems news stories on BioPortfolio along with dozens of Advanced Targeting Systems Clinical Trials and PubMed Articles about Advanced Targeting Systems for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advanced Targeting Systems Companies in our database. You can also find out about relevant Advanced Targeting Systems Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record